Abivax S.A. (ABVX) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Abivax S.A. (ABVX) stock forecast summary
Our AI ranks Abivax S.A. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Abivax S.A. is a mid-cap company with a market capitalization of $7.74B. It ranks number 40 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For ABVX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -17.0%, measured on 218 forecast dates between 2025-03-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 4.0%, measured on 261 forecast dates between 2025-03-28 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ABVX included.
Follow ABVX freeABVX price chart and AI forecast
How ABVX ranks among 5171 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Abivax S.A. (ABVX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric. Statement values were filed in EUR and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
Valuation & Market
| Metric | ABVX | Rank |
|---|---|---|
| Market Cap | $7.74B | 40/60 |
| EPS | $-9.65 | – |
| FCF/Share | $-5.16 | – |
Profitability & Margins
| Metric | ABVX | Rank |
|---|---|---|
| ROE | -129.7% | 34/38 |
| ROA | -101.0% | 42/43 |
| ROIC | -80.7% | 43/46 |
| Tax Rate | -1.0% | – |
Financial Health
| Metric | ABVX | Rank |
|---|---|---|
| Current Ratio | 8.75x | 13/59 |
| Financial Leverage | 1.28x | 34/48 |
| Working Capital | $574M | 40/59 |
Cash Flow
| Metric | ABVX | Rank |
|---|---|---|
| Operating Cash Flow | -$452M | 54/59 |
| Free Cash Flow | -$452M | 45/50 |
| Capital Spending | -$340K | 5/50 |
Income Statement
| Metric | ABVX | Rank |
|---|---|---|
| Operating Income | -$476M | 45/51 |
| Net Income | -$669M | 40/46 |
| R&D Expense | $353M | 36/58 |
Dividend & Shareholder Information
| Metric | ABVX | Rank |
|---|---|---|
| Shares Outstanding | 88M | – |
Balance Sheet Highlights (USD millions, converted from EUR)
| Total Current Assets | $648M | |
| Cash & Short-term Investments | $607M | |
| Short-term Debt | $30M |
ABVX quarterly financials and insider trading
Abivax S.A. (ABVX) industry peers
Companies classified under the same SEC industry code as Abivax S.A. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ABVX Abivax S.A. | ▼ | $7.74B |
| LLY Eli Lilly & Co | ▶ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $610.38B |
| ABBV Abbvie Inc. | ▶ | $504.46B |
| MRK Merck & Co., Inc. | ▲ | $358.21B |
| NVS Novartis Ag | ▼ | $286.95B |
| AZN Astrazeneca Plc | ▼ | $256.39B |
| ABT Abbott Laboratories | ▼ | $182.37B |
| NVO Novo Nordisk A S | ▼ | $174.29B |
| PFE Pfizer Inc | ▶ | $167.80B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▶ | $128.95B |
| BMY Bristol Myers Squibb Co | ▶ | $122.05B |
| GSK Gsk Plc | ▼ | $100.46B |
| SNY Sanofi | ▼ | $99.33B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $82.34B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $60.76B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.91B |
| ONC Beone Medicines Ltd. | ▲ | $42.53B |
| ZTS Zoetis Inc. | ▼ | $32.40B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.02B |
| RPRX Royalty Pharma Plc | ▶ | $26.29B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.59B |
| GMAB Genmab A/S | ▲ | $23.80B |
| UTHR United Therapeutics Corp | ▶ | $23.23B |
| INSM Insmed Inc | ▶ | $21.67B |
| VTRS Viatris Inc | ▼ | $20.93B |
| ASND Ascendis Pharma A/S | ▲ | $14.85B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.92B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.98B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.26B |
| CORT Corcept Therapeutics Inc | ▲ | $11.91B |
| ELAN Elanco Animal Health Inc | ▼ | $11.77B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.77B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.62B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.58B |
| TGTX Tg Therapeutics, Inc. | ▲ | $8.89B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.84B |
| CYTK Cytokinetics Inc | ▲ | $8.61B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.23B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $7.90B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.33B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.06B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.93B |
| ALKS Alkermes Plc. | ▲ | $6.92B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.24B |
| AMRX Amneal Pharmaceuticals, Inc. | ▲ | $6.13B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▲ | $6.06B |
| LGND Ligand Pharmaceuticals Inc | ▶ | $5.95B |
| BLTE Belite Bio, Inc | ▲ | $5.62B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.35B |
| COGT Cogent Biosciences, Inc. | ▶ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▲ | $5.09B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.89B |
| MANE Veradermics, Inc | ▲ | $4.81B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.72B |
| ERAS Erasca, Inc. | ▲ | $4.68B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.04B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.03B |
| INDV Indivior Pharmaceuticals, Inc. | ▶ | $3.97B |
| TNGX Tango Therapeutics, Inc. | ▲ | $3.83B |
Where ABVX sits on the market map
Abivax S.A. (ABVX) stock news
Loading...
Abivax S.A. (ABVX) stock forecast FAQ
What is the Abivax S.A. (ABVX) stock forecast?
Our AI ranks Abivax S.A. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Abivax S.A. stock predictions?
For ABVX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -17.0%, measured on 218 forecast dates between 2025-03-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 4.0%, measured on 261 forecast dates between 2025-03-28 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Abivax S.A. forecasts updated?
Abivax S.A. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Abivax S.A.'s industry peers?
60 issuers in our coverage, ABVX included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.